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Sustainable development goals 
s u m m a r y 
Objectives: Prompted by international targets for elimination of hepatitis B virus (HBV), we set out to 
characterise individuals with HBV monoinfection vs. those coinfected with HBV/HIV, to evaluate the im- 
pact of therapy and to guide improvements in clinical care. 
Methods: We report observational data from a real world cross-sectional cohort of 115 adults with 
chronic hepatitis B infection (CHB), at a university hospital in Cape Town, South Africa. HIV coinfection 
was present in 39 (34%) subjects. We recorded cross-sectional demographic, clinical and laboratory data. 
Results: Compared to those with HIV coinfection, HBV monoinfected adults were less likely to be HBeAg- 
positive (p = 0.01), less likely to have had assessment with elastography (p < 0.0 0 01), and less likely to be 
on antiviral treatment (p < 0.0 0 01); they were more likely to have detectable HBV viraemia (p = 0.04), and 
more likely to have features of liver disease including moderate/severe thrombocytopaenia (p = 0.007), 
elevated bilirubin (p = 0.004), and elevated APRI score (p = 0.02). Three cases of hepatocellular carcinoma 
all arose in HBV monoinfection. 
Conclusions: Our data demonstrate that individuals with HBV monoinfection may be disadvantaged com- 
pared to those with HIV coinfection, highlighting potential systematic inequities in referral, monitoring 
and treatment. 
© 2020 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. 
























The burden of chronic infection with hepatitis B virus (HBV) in
outhern Africa is high, and in this setting the distribution overlaps
ith populations in which HIV infection is prevalent. 1 Due to high
ates of coinfection, and the overlap in antiviral regimens, there
s a pressing need to develop an enhanced understanding of the
nterplay between these infections, and to capitalise on opportu-
ities for deploying existing HIV infrastructure to improve HBV
iagnosis, clinical care and prevention. International Sustainable∗ Corresponding author. 
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 http://creativecommons.org/licenses/by/4.0/ ) evelopment Goals set targets for elimination of HBV as a public
ealth problem by the year 2030. 2 Developing insights into the
haracteristics and outcomes of chronic HBV (CHB) monoinfec-
ion and HBV/HIV coinfection in real world settings, including
ower/middle income countries (LMIC), will underpin improved
trategies for monitoring, prognostication, patient stratification
nd therapy. 
A traditional paradigm suggests that individuals with HBV/HIV
oinfection might have a worse prognosis from chronic liver
isease than those with HBV monoinfection, typically linked
ith higher rates of HBeAg-positivity and higher viral loads, 1 , 3 
ower CD4 + T cell counts, increased incidence of liver fibrosis 4 
nd hepatocellular carcinoma (HCC), higher rates of vertical HBVn Association. This is an open access article under the CC BY license. 














































































































transmission, and higher overall mortality in those with HIV
coinfection. 5 However, this picture is not consistent between
populations (even within individual studies) 6 and the interplay
between viruses may be affected by specific characteristics of
the host or viral population, 7 as well as by changes in treatment
guidelines over time. 
Lamivudine (3TC) and tenofovir (most commonly in the form of
tenofovir disoproxil fumarate, TDF) are nucleos(t)ide reverse tran-
scriptase inhibitor (NRTI) agents with established track records of
safety and tolerability in both HIV and HBV infection. Long-term
3TC use is hampered by a high rate of selection of resistance, 8 
while TDF is favoured as the genetic barrier to resistance is high. 9 
HIV treatment is now initiated irrespective of clinical or immuno-
logical status, 10 underpinned by ‘90-90-90’ targets, seeking to have
90% of cases diagnosed, 90% of these on treatment, and 90% of
these virologically suppressed. 11 
TDF is one of the recommended choices for the NRTI backbone
of first line cART for HIV. 12 In South Africa, second line NRTI com-
binations also include TDF or 3TC, 13 and national ART guidelines
recommend HBsAg testing for patients switching from a first line
regimen to avoid acute hepatitis flares in case of TDF withdrawal.
In HBsAg positive individuals, TDF is continued as a component of
second line cART. Thus the majority of those with HIV/HBV coin-
fection receive TDF, either as routine first-line therapy, or incorpo-
rated into second-line regimens. 
In contrast, for HBV monoinfection, TDF is prescribed only for
a subset of patients, based on algorithms that incorporate assess-
ment of the patient (age and sex), virologic status (HBV DNA viral
load) and the presence of underlying fibrotic or inflammatory liver
disease (ALT, elastography score, ultrasound appearance, biopsy re-
sults). 14–16 WHO targets for 2030 aim for 90% of HBV cases to be
diagnosed, and for 80% of those eligible for treatment to be re-
ceiving it. 17 However, only a small minority of those living with
CHB are currently aware of their status, and laboratory and radi-
ological assessment are not accessible in many settings. 18 Current
assessment using WHO guidelines therefore typically misses a high
proportion of patients who should be treated. 19 
Recognising the need for improved characterisation of CHB in-
fection, both alone and in combination with HIV coinfection, we
have undertaken a cross-sectional observational analysis of adults
with CHB in an urban setting in South Africa. We set out to explore
the differences between individuals with monoinfection and coin-
fection, and to identify inequities that may arise as a combined re-
sult of referral bias and differences in care provision. Our approach
included specific focus on the influence of discrepancies between
HBV and HIV guidelines for antiviral therapy. Our aim is to identify
areas in which local and regional clinical practice can be strength-
ened, with the wider potential to inform future guidelines for care
of adults with CHB. 
Methods 
Clinical cohort 
We undertook a real world study, representing a cross-sectional
observation of adults in clinical care at Tygerberg Hospital, a ter-
tiary referral hospital in Cape Town, South Africa. We recruited
adults with CHB infection, with or without HIV coinfection, at-
tending routine clinical follow-up in hepatology and infectious dis-
eases outpatient clinics. Healthcare workers at local HIV and pri-
mary care clinics within the referral area are encouraged to send
all patients diagnosed with HIV-HBV coinfection to the Tygerberg
Division of Infectious Diseases clinic for counselling and baseline
investigations including clinical assessment, laboratory tests and
elastography. Surrounding clinical centres also refer adults testing HBsAg-
ositive for assessment and follow-up in the Division of
astroenterology. Patients are followed at the clinic at inter-
als according to the baseline findings, typically attending at
ntervals of six months. Thus, our cohort represents prevalent
hronic disease in this community, rather than new incident in-
ections. Cases were defined as being HBsAg-positive (having been
nder follow-up for a period of > 6 months) and were recruited
nto a cross-sectional cohort (Oxford-South Africa Hepatitis Cohort,
OxSA-Hep’), commencing July 2018. We here present the results of
 planned interim analysis of data after 12 months of recruitment. 
We recorded treatment with antiviral therapy at the time of re-
ruitment to the study, routine clinical laboratory data (including
erological markers of HBV infection, creatinine, liver function tests
nd platelet count), and documented elastography scores when
he patient had been assessed by fibroscan. We recorded data in
 LabKey database, 20 using a unique pseudonymised patient ID
umber. 
eneration and analysis of laboratory data 
Biochemical and serological data were generated on the Cobas
0 0 0 series e601 module analyzer (Roche Diagnostics GmbH, Ger-
any), including alanine aminotransferase (ALT) and aspartate
minotransferase (AST) and serum bilirubin (BR). Platelet counts
ere obtained using the Advia 2120i analyzer (Siemens Healthcare
iagnostics Inc, USA). HIV and HBV viral loads were measured us-
ng Cobas Ampliprep/Taqman tests (Roche Molecular Diagnostics,
he Netherlands). 
Local guidelines were used to define thresholds. 21 We defined
he upper limit of normal (ULN) for ALT as 19 U/L for females and
0 U/L for males, 16 , 14 ULN for AST as 40 U/L, ULN for BR as 17
mol/L. We calculated liver fibrosis scores, AST to Platelet Ratio
ndex (APRI) and Fibrosis-4 (FIB-4) as follows: 
• APRI = (AST / ULN AST) / (Platelet count x 100) 
• FIB-4 = (Age in years x AST) / (Platelet count ∗ √ ALT) 
We used thresholds of FIB-4 > 3.25 (97% specificity, and positive
redictive value of 65% for advanced liver fibrosis 22 ), and APRI > 2
91% specific for cirrhosis). 23 , 24 
We measured renal function based on estimated glomerular fil-
ration rate (eGFR) as follows: 
• 186 x (creatinine (μmol/L)/88.4) −1.154 x (age in years) −0.203 x
(0.742 if female) x (1.210 if black). 25 
Normal renal function is defined as eGFR ≥ 90 ml/min/1.73m 2 .
e grouped together individuals with renal impairment, defined
s chronic kidney disease (CKD) Stage II (eGFR 60-89 ml/min) or
tage III (eGFR 30-59 ml/min). We defined moderate/severe throm-
ocytopaenia as a platelet count < 75 × 10 3 /μl. 26 
lastography and imaging 
Elastography to quantify liver stiffness (an assessment of in-
ammation and/or fibrosis) is not undertaken consistently in this
etting, but is performed in a subset of patients at the discretion of
he clinical team using the Fibroscan 402 (Echosens, Paris, France).
lastography scores are not reliable in individuals with a high body
ass index or during pregnancy, and would not be undertaken
n these circumstances. Due to the cross-sectional nature of the
ohort, we recorded elastography scores at a single time point
nly. HCC screening is not undertaken as part of routine practice,
s access to imaging and biomarkers for surveillance is limited.
herefore, a diagnosis of HCC is usually made on the basis of an
bserved deterioration in clinical status or laboratory markers,
ollowed by imaging in selected cases. 

















































































































u  reatment indications and outcomes 
We have referred to HBV treatment recommendations pub-
ished by the UK National Institute for Clinical Excellence (NICE), 14 
he European Association for the Study of the Liver (EASL), 15 and
outh African national guidelines. 16 All concur in advising tenofovir
r entecavir as first-line options, and recommend that stratifica-
ion for therapy should be based on laboratory parameters, on the
resence and extent of existing liver disease assessed by imaging
nd/or biopsy, and on consideration of other individual clinical and
emographic factors. 
Due to resource constraints, liver biopsy is rarely undertaken in
his setting and we have primarily used laboratory parameters to
ssess treatment eligibility. South African guidelines suggest con-
ideration of therapy for individuals who are HBeAg-positive with
BV DNA > 20,0 0 0 IU/ml and ALT above ULN, or who are HBeAg-
egative with HBV DNA > 2,0 0 0 IU/ml and ALT above ULN, with the
im of achieving durable suppression of HBV DNA to low or un-
etectable levels and normalisation of ALT. 16 Individuals with HIV
oinfection are routinely treated with first line cART that includes
BV-active agents. 13 In practice in this setting, TDF is therefore
rst line therapy for CHB, both in the presence and absence of HIV
nfection. 
tatistical analysis 
We analysed data using GraphPad prism v 8.0.1. For continuous
ariables, we used Mann Whitney Test; for categorical variables we
sed Fisher’s Exact Test. Linear regression was used to assess asso-
iations between two continuous variables. For multivariate anal-
sis, we performed multivariate logistic regression using bayesglm
unction of the R package. 
thics 
Ethics approval was provided by University of Oxford Tropi-
al Research Ethics Committee (ref. OXTREC 01-18) and Stellen-
osch University Human Research Ethics Committee (HREC ref.
17/01/013). All participants provided written valid informed con-
ent. A STROBE statement to support the quality of this observa-
ional study is provided (Suppl. Table 1). 
esults 
epresentation of HBV monoinfection and HIV/HBV coinfection in an 
dult cohort 
We recruited 115 adults with HBV infection (57% male), rep-
esenting 76 adults with HBV monoinfection (66%) and 39 with
BV/HIV coinfection (34%) ( Fig. 1 ; Table 1 ). The full metadata for
his cohort are available in Suppl. Table 2. The majority of partic-
pants were of South African origin (98/115, 85%; Suppl. Fig. 1).
here was no significant difference in sex, age or body weight be-
ween the monoinfected and coinfected groups (p = 0.24, 0.51, and
.23 respectively; Table 1 ). HBeAg-positive status was significantly
ore common among individuals with HIV coinfection (39%) com-
ared to HBV monoinfected individuals (14%); (p = 0.01; Table 1 ;
ig. 2 A). 
ntiviral therapy and virologic outcomes in HBV monoinfection vs 
IV/HBV coinfection 
Duration of antiviral therapy was recorded for 36 individuals
ith HBV monoinfection and 37 individuals with HIV coinfection
median 38 vs. 62 months, respectively; p = 0.1). As anticipated,ased on HIV treatment guidelines, 13 a significantly greater pro-
ortion of the coinfected group was on antiviral therapy compared
o the monoinfected group (97% vs. 47% respectively, p < 0.0 0 01;
ig. 2 B; Table 2 ). Accordingly, HBV DNA was more likely to be sup-
ressed below the limit of detection in coinfected than monoin-
ected patients (53% vs 30%, respectively; p = 0.04; Fig. 2 C; Table 2 ),
nd absolute values for HBV DNA viral load (VL) were also sig-
ificantly lower in the coinfected group than the monoinfected
p = 0.04; Suppl Fig. 2A; Table 2). 
In the HBV/HIV coinfected group, 38/39 adults were on antiviral
herapy that included HBV-active agents (TDF and/or 3TC); one
atient was not on therapy. HIV VL data were available for 35/38,
eing undetectable in 22/35 (63%), and detectable but < 10 0 0 RNA
opies/ml in a further 5/35 (14%). Overall, suppression of HIV vi-
aemia was associated with suppression of HBV viraemia (p = 0.01,
ig. 2 D; Suppl Fig. 2B). Among individuals with undetectable HIV
L, HBV DNA was still detectable in 6/21 (29%). Among these, one
as being treated with 3TC as the only HBV-active agent, with
BV DNA VL 1.0 × 10 5 IU/ml. Suppression of HIV viraemia suggests
easonable adherence to cART, and the high HBV viral load may
herefore be consistent with 3TC resistance. The other five were
eceiving TDF-based combination therapy, making drug resistance
 less likely explanation for HBV viraemia (HBV VL 20-54 4 4
U/ml). Treatment start date was ≥15 months prior to the date of
ecruitment (recorded in all 6 cases), making it unlikely that HBV
iraemia was detectable because therapy had only recently been
nstituted. 
roportion of untreated HBV monoinfected patients who meet 
reatment criteria 
We reviewed the data for 38 HBV monoinfected individuals off
herapy to determine the proportion of these who met treatment
riteria. Using South African guidelines, 16 8/38 (21%) were treat-
ent eligible, comprising individuals with ALT > ULN of whom four
ere HBeAg-positive with HBV DNA > 20,0 0 0 IU/ml, and four were
BeAg-negative with HBV DNA > 2,0 0 0 IU/ml. 
revalence of liver disease: laboratory data 
We assessed laboratory data and elastography scores as markers
or underlying liver disease. There was no significant difference in
LT or AST between monoinfected vs. coinfected individuals (p = 0.8
nd p = 0.6, respectively). For BR, the absolute values were signifi-
antly higher in those with monoinfection (p = 0.004), and a higher
roportion of the population had an elevated value in the mon-
nfected group (23%) vs. the coinfected group (8%), although this
ifference did not reach statistical significance (p = 0.06); Fig. 3 A,C.
hrombocytopaenia can be an indicator of chronic liver disease as
 result of a variety of mechanisms, including splenic sequestration
nd myelosuppression. 26 Strikingly, all the individuals with mod-
rate/severe thrombocytopaenia were in the HBV monoinfected
roup, representing 16% of this group vs. 0% in those with coin-
ection (p = 0.007); Fig. 3 B,D, suggesting a subgroup of individuals
ith established liver disease. 
We calculated fibrosis scores from laboratory data, finding a sig-
ificantly higher proportion of the HBV monoinfected group had
PRI scores predictive of cirrhosis (p = 0.02; Fig. 4 A). There was
 trend in the same direction, although non-significant, for FIB-4
p = 0.1, Fig. 4 B). 
revalence of liver disease: elastography and clinical data 
Due to limited clinical availability, elastography is not routinely
ndertaken, and data were only available in 48/115 patients (42%).
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Fig. 1. Summary of cohort of 115 adults with HBV infection from Cape Town, South Africa, showing numbers with HBV monoinfection and HIV/HBV coinfection, those 
receiving therapy and those with suppressed viraemia. Viral load data were not available in 12 cases, of whom 7 were HBV monoinfected and 5 were HBV/HIV coinfected 
(shown in dashed lines and box). Green boxes indicate number with viraemia suppressed below the limit of detection, yellow indicate number with one virus suppressed 
and the other detectable, red indicate number with no viraemic suppression. 
Table 1 
Summary of clinical and laboratory parameters recorded from a cohort of 115 adults with HBV infection in Cape Town, South Africa, comparing groups with 
HBV monoinfection (n = 76) versus HIV/HBV coinfection (n = 39). For extended version of table, see Suppl data table 3. 
Whole Cohort HBV monoinfection HIV/HBV coinfection p-value a 
Sex M:F (% male) 65:50 (57%) 46:30 (61%) 19:20 (49%) 0.24 
Median age in years at enrollment b (IQR) 44 (36-53) 45 (35-54) 41 (37-50) 0.51 
Median body weight in kg c (IQR) 73 (60-84) 75 (60-86) 71 (60-80) 0.23 
Proportion HBeAg positive d (%) 22/107 (21%) 9/70 (13%) 13/37 (35%) 0.011 
Proportion with elevated ALT above ULN e (%) 52/113 (46%) 36/74 (49%) 16/39 (41%) 0.55 
Proportion with elevated AST above ULN f (%) 31/95 (33%) 20/58 (35%) 11/37 (30%) 0.66 
Median BR g , mmol/L (IQR) 7 (5-14) 9 (6-17) 5 (4-9) 0.004 
Proportion with elevated BR > ULN g (%) 19/109 (17%) 16/70 (23%) 3/39 (8%) 0.06 
Median platelet count h , x10 3 / μl (IQR) 236 (163-297) 227 (156-294) 240 (170-307) 0.41 
Proportion with thrombocytopaenia h (%) 11/106 (10%) 11/67 (16%) 0/39 (0%) 0.007 
Proportion with APRI score > 2 8/92 (9%) 8/55 (15%) 0/37 (0%) 0.02 
Proportion with FIB-4 score > 3.25 21/92 (23%) 16/55 (29%) 5/37 (14%) 0.13 
Proportion assessed by elastography i (%) 48/115 (42%) 13/76 (17%) 35/39 (90%) < 0.0001 ∗
Median elastography score, kPa (IQR) 6.1 (4.8-9.0) 7.8 (5.4-10.3) 5.8 (4.5-8.2) 0.15 
Proportion with elastography score > 9kPa (%) 12/48 (25%) 5/13 (38%) 7/35 (20%) 0.26 
Proportion with hepatic complications j (%) 20/112 (16%) 15/73 (21%) 5/39 (13%) 0.12 
Proportion with CKD stage II or III k 16/111 (14%) 9/72 (13%) 7/39 (18%) 0.79 
IQR = inter-quartile range; ALT = alanine transferase; ULN = upper limit of normal. 
a p-value for categorical variables by Fisher’s Exact Test, and for continuous variables by Mann Whitney test. 
b Age available for 115 individuals. 
c Body weight available for 111/115 individuals. 
d HBeAg status available for 107/115 individuals. 
e ALT available for 113/115 individuals, with ULN defined as 19 iu/ml for females and 30 iu/ml for males. 
f AST available for 95/115 individuals, with ULN defined as 40 iu/ml. 
g BR available for 109/115 individuals; ULN defined as 17 mmol/L. 
h Platelet count available for 106/115 individuals; moderate/severe thrombocytopaenia defined as platelet count < 75 × 10 3 / ul 27 . 
i Elastography data available for 50/119 individuals. 
j Hepatic complications reviewed for 108/112 individuals, defined as a documented diagnosis of HCC and/or cirrhosis. 
k CKD (chronic kidney disease) stages II and III defined as eGFR < 90 ml/min/1.73m 2 . 

















Individuals with HBV/HIV coinfection were more likely to have
been assessed by elastography, in whom it was undertaken in
35/39 cases (90%) compared to only 13/76 (17%) of individuals with
HBV monoinfection (p < 0.0 0 01; Table 1 ). The median elastogra-
phy score was higher in the HBV monoinfected group compared
to those with coinfection (7.8 kPa vs 5.8 kPa), and a greater pro-
portion of the HBV monoinfected group met the stringent treat-
ment threshold of 6 kPa (9/13 (64%) monoinfected vs. 16/35 (47%)oinfected patients). 14 Neither of these differences reached statisti-
al significance (p = 0.2, in both cases), but this comparison is lim-
ted by small numbers. There was no difference in ALT values be-
ween the monoinfected vs coinfected patients with documented
broscan scores (median ALT 22 vs. 23 U/L, respectively), suggest-
ng that elastography was not systematically undertaken for HBV
onoinfected patients with biochemical evidence of inflammatory
iver disease. 
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Fig. 2. Characteristics of adults with CHB, based on HBeAg status, HBV therapy and virologic response to therapy, comparing those with HBV monoinfection vs HBV/HIV 
coinfection from a cross-sectional study in Cape Town, South Africa. A: Proportion of each group testing HBeAg-positive. B: Proportion of monoinfected vs coinfected adults 
receiving antiviral therapy; C: Proportion of monoinfected vs coinfected adults with HBV DNA viral load suppressed below the limits of quantification ( < 20 IU/ml) on antiviral 
therapy. D: HBV/HIV co-infected individuals only, showing proportion who have suppressed HIV and/or HBV viral load below the limit of quantification on antiviral therapy. 
In all cases, p-values calculated by Fisher’s Exact Test, and the number of individuals represented in each group is shown in brackets below the columns. 
Table 2 
Summary of antiviral therapy treatment and outcomes from a cohort of 115 adults with HBV infection in Cape Town, South Africa, comparing features of those 
with HBV monoinfection (n = 76) versus HIV/HBV coinfection (n = 39). 
Whole Cohort HBV monoinfection HIV/HBV coinfection p-value a 
Proportion on antiviral treatment b (%) 72/111 (65%) 34/72 (47%) 38/39 (97%) < 0.0001 ∗
Median duration of therapy c , months (IQR) 45 (25-77) 38 (17-69) 62 (29-81) 0.11 
Median HBV DNA viral load IU/ml d (range) 42 (0-1.7 × 10 8 ) 86 (0-1.7 × 10 8 ) 0 (0-1.1 × 10 8 ) 0.04 
Proportion of HBV viraemia undetectable e 41/107 (38%) 21/69 (30%) 20/38 (53%) 0.04 
a p-value for categorical variables by Fisher’s Exact Test, and for continuous variables by Mann Whitney test. 
b Antiviral treatment data available for 111/115 individuals. 
c Duration of therapy defined for 36 HBV monoinfected and 37 HBV/HIV coinfected individuals. 
d HBV DNA viral load available for 69/76 HBV monoinfected and 38/39 HIV coinfected individuals. 
e Undetectable HBV DNA defined as viral load in serum below limit of detection of assay (typically HBV DNA < 20 IU/ml). 



















We reviewed clinical records for complications reported by spe-
ialist doctors in 112/115 cases (data not available for three pa-
ients). Among these, 20/112 (18%) had hepatic complications of
BV infection, including 18 cases of cirrhosis (16% prevalence) and
 cases of HCC (3% prevalence); two patients had both cirrho-
is and HCC. The prevalence of hepatic complications was almost
wice as high in HBV monoinfection (15/73; 21%) compared to
BV/HIV coinfection (5/39; 13%), although this difference did not
each statistical significance due to small numbers in each groupp = 0.1; Table 1 ). All HCC arose in males (age 30, 53 and 60) and
ccurred in the context of HBV monoinfection. One patient with
oth HCC and cirrhosis was on TDF therapy, whereas the other
wo were untreated at the time of data collection. Due to the
mall numbers and relatively short duration of follow-up, we can-
ot draw any conclusions regarding the risk factors or epidemiol-
gy of HCC based on this study, but the HCC arising in a 30-year
ld is consistent with the early age at which this malignancy arises
n sub-Saharan African populations. 27 
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Fig. 3. Assessment of liver disease in adults with HBV monoinfection vs HBV/HIV coinfection in a cross-sectional study in Cape Town, South Africa based on serum bilirubin 
and platelet count. BR - serum bilirubin; Plt - platelet count. Panels A and B: p-values by Fisher’s Exact Test comparing the number in each group falling above and below 
specified thresholds (BR > 17 mmol/L; moderate/severe thrombocytopaenia defined as plt < 75 × 10 3 /μl). Number in each group indicated in brackets under the columns; 
this varies according to data availability. Panels C and D: p-values by Mann Whitney test; bars indicate median and IQR. Pale yellow shading shows population defined as 
following outside reference range. C: serum bilirubin levels are significantly elevated in the group with HBV monoinfection. D: Distribution of plt highlights all of those with 


























c  Evidence of renal dysfunction 
Chronic kidney disease (CKD) can arise in association with HIV
infection, and is also a potential side effect of TDF therapy. 28 
Therefore, we examined this cohort for the presence of CKD based
on calculation of eGFR, available for 111 individuals. Due to small
numbers, we grouped together CKD stage II and III, finding a preva-
lence of 16/111 (14%). There was no difference in the prevalence
of CKD between individuals with HBV monoinfection vs. HBV/HIV
coinfection (CKD prevalence 9/72 (13%) vs. 7/39 (18%), respectively,
p = 0.6), and no evidence of nephrotoxicity among those on TDF
(CKD present in 9/65 (14%) of treated individuals, vs. 7/43 (16%)
of untreated; p = 0.8). While we cannot exclude the possibility that
selection bias for treatment might mean TDF is more frequently
started in individuals with normal renal function, these results are
nevertheless reassuring in suggesting no significant on-treatment
nephrotoxicity. ultivariate analysis 
Based on small numbers, we were underpowered to identify
ignificant associations based on multivariate analysis. However,
he relationship between HBV/HIV coinfection and undergoing as-
essment by elastography and being prescribed antiviral therapy
emained significant on multivariate analysis ( Tables 1 and 2 , foot-
otes). 
iscussion 
ontext and primary conclusions 
Developing a detailed understanding of the characteristics of
HB, and the clinical interplay with co-endemic HIV, is important
o drive forward improvements in care provision. Although suc-
essful HBV vaccination campaigns are well established, modelling
T.G. Maponga, A.L. McNaughton and M. van Schalkwyk et al. / Journal of Infection 81 (2020) 121–130 127 
Fig. 4. Assessment of liver disease using fibrosis scores derived from laboratory data in adults with HBV monoinfection vs HBV/HIV coinfection in a cross-sectional study of 
adults in Cape Town, South Africa. APRI - AST to Platelet Ratio Index; FIB-4 - Fibrosis-4 score (for formulae, see methods). Number in each group indicated in brackets under 
the columns; this varies according to data availability. Panels A and B: p-values by Fisher’s Exact Test comparing the number in each group falling above and below the 
threshold for cirrhosis/fibrosis (APRI > 2; FIB-4 > 3.25). Panels C and D: p-values by Mann Whitney test and bars indicate median and IQR. Pale yellow shading shows pop- 
ulation defined as falling above the defined threshold for liver disease. No significant difference in median value for either score, but the scatter plots show that individuals 










































f  tudies predict long timeframes to elimination. 29 , 30 This cross-
ectional cohort provided an opportunity to make real world com-
arisons between adults with HBV monoinfection and HBV/HIV
oinfection, and to reflect on the systematic inequities and dif-
erences in the structure of clinical care provision which might
ontribute to different disease outcomes. 
In this setting, we confirmed a significantly higher prevalence
f HBeAg-positive status in those with HIV coinfection, associated
ith higher HBV viral loads and acceleration of inflammatory or
brotic liver disease. However, the observational data we have col-
ected indicate that - in this setting - the monoinfected group
s disadvantaged compared to those with coinfection. Worse out-
omes in HBV monoinfection may stem from the sustained neglect
f HBV as a public health problem, 18 complex algorithms for HBV
reatment stratification, inconsistent access to TDF therapy, 31 and
eferral bias. It seems likely that the broad patterns we observe are
eneralisable across southern Africa, given the widespread invest-
ent that has been made in HIV infrastructure versus the lack of
onsistent HBV services. However, our focus on an urban tertiary
eferral centre is situation-specific, and more data are required to
xplore different regional patterns. A previous report also documents elevated rates of severe fi-
rosis in HBV monoinfected compared to their HBV/HIV coinfected
ounterparts, 32 although this observation is not consistent between
ettings. 4 The reduced liver disease we observed in coinfected in-
ividuals highlights the positive impact of wider treatment ac-
ess, which whilst prescribed to treat HIV, is also inadvertently
uppressing HBV. In recent years, there have been increased calls
or the integration of hepatitis care into HIV programmes, in or-
er to capitalise on pre-existing infrastructure for screening and
reatment. 33 , 34 Previous studies have indicated that < 25% of HIV-
ositive individuals are likely to be screened for HBsAg, 35 indicat-
ng that integration of the screening programmes may be of benefit
o both coinfected and monoinfected patients. 
We found no difference in the prevalence of elevated hep-
tic transaminases between monoinfected and coinfected patient
roups. It is important to recognise that appropriate thresholds for
he ULN of liver enzymes have not been clearly determined for
frican populations, 21 and that significant evidence of progressive
iver disease can be present even in the absence of abnormalities
n liver enzymes. This highlights the lack of sensitivity of liver
unction tests as biomarkers; clinical surveillance may need to















































































































t  incorporate other markers, laboratory-based fibrosis scores, and/or
or elastography results. 
HCC in HBV infection 
HCC can arise independent of liver fibrosis, 16 and therefore even
among HBV-infected individuals with no objective evidence of in-
flammatory or fibrotic liver disease, there is a potential for the
emergence of malignancy. In this study, HCC was only documented
in three patients so we are unable to draw conclusions that can
be generalised, but we note that it arose only in the context of
HBV monoinfection. Treatment with nucleoside analogues has been
shown to lower the risk of HCC. 36 Our results suggest that adults
with HBV monoinfection may be coming to clinical care too late,
and may not have sufficient access to antiviral therapy even when
enrolled in clinical care. Further investigation is warranted, but our
observations underline a pressing need for simplified, scalable ap-
proaches to early HBV diagnosis and treatment. 37 
HBV suppression on therapy 
Despite the immunological defect associated with HIV infection
(associated with loss of CD4 + T cells) and the higher prevalence
of HBeAg + status in this group, HBV viraemia can be successfully
suppressed in the majority of coinfected patients using conven-
tional TDF-based cART regimens. However, even on appropriate an-
tiviral therapy, over a quarter of patients still had detectable HBV
viraemia. TDF therapy can be slow to suppress HBV DNA to be-
low the limits of detection, 38 but given the median exposure of 15
months, the HBV viraemia we observed on therapy is more likely
to be explained by suboptimal adherence to therapy, pharmacoki-
netics (drug absorption, levels within liver tissue), or drug resis-
tance. Conclusions about adherence must be made with caution, as
HIV rebound takes much longer than HBV in patients on efavirenz
(EFV), due to the long half-life of this agent, that may be extended
still further in patients with CYP2B6 mutations. 
Even on treatment, HBV is more likely to be suppressed in the
context of HIV co-infection, perhaps related to better support and
education around treatment adherence, or potentially to therapy
with more than one HBV active agent (TDF + 3TC) in the co-infected
group. Careful clinical surveillance, with checking and reinforce-
ment of therapy, is therefore important. There is also a need to
consider a potential role for dual HBV therapy, and to evaluate the
currently uncertain impact of TDF resistance. 8 , 39 
Changes to cART regimens with influence on HBV therapy 
Changes to cART recommendations are developing, based on
the success of dolutegravir (DTG), both in the context of prior
viraemic suppression 40 and for salvage after failure of first-
line treatment. 41 , 42 DTG/3TC is a common combination, but
other regimens do not contain any first-line HBV active agents,
(e.g. DTG + rilpivirine (RPV), 43 emtricitabine (FTC), 44 or ritonavir-
boosted lopinavir (LPVr) 42 ). These regimens are deemed inappro-
priate in the context of HBV coinfection, 45 although there are data
demonstrating a potential role for FTC together with TDF in medi-
ating HBV suppression. 46 As dual therapy combinations enter clin-
ical practice for HIV treatment in Africa, enhanced awareness and
scrutiny will be critical to ensure that HBV-positive individuals are
diagnosed and receive appropriate treatment. 
Drug resistance 
We identified a patient with phenotypic evidence of 3TC-
resistant HBV, consistent with the well-documented selection of
resistance by 3TC monotherapy, 47 and in keeping with anotherfrican study that documented a high prevalence of 3TC resistance
mong coinfected patients 4 . TDF resistance is less well substanti-
ted, and can be difficult to confirm phenotypically due to the slow
ate of HBV DNA suppression after institution of therapy; how-
ver, there are reports confirming the potential for resistance to
his agent. 8 , 39 
aveats and limitations 
We have studied a small cohort, representing a distinct ge-
graphical setting and focusing on clinical care delivery within
he specific environment of a tertiary care university hospital. The
tudy design was observational, incorporating the influence of bias
n referral patterns and clinical follow-up, and capturing the influ-
nce of systematic differences in guidelines for HBV and HIV man-
gement. Based on this cross-sectional view, long-term outcomes
f liver disease can only be extrapolated with caution. We have
ot been able to capture data regarding important influences on
BV and HIV viral loads, including compliance with treatment and
he presence of antiviral resistance. HBV genotype data were not
vailable, but may add future insights. 7 , 48 In the longer term, it
ould be desirable to undertake prospective studies in larger co-
orts, based on more robust, reproducible measures of liver disease
hat have been well validated for the population in question. 
Even in the context of an urban teaching hospital, missing data
re problematic. Assessment with elastography is not consistently
eployed, and serological markers are expensive, and not routinely
ndertaken at each clinic visit. The difference in fibroscan rates
etween monoinfected and coinfected patients most likely relates
o the combined influence of differences in staffing, resources and
quipment. It is also possible that this practice is influenced by a
reater perceived risk of developing inflammatory liver conditions
n coinfected patients. 49 Amongst the coinfected group, who were
ore likely to have undergone assessment, 10% of individuals were
evertheless still lacking elastography results. We were unable to
etermine specific treatment duration for a proportion of the pa-
ients studied, adding to uncertainty about exposure to antiviral
herapy in HBV and HBV/HIV infected groups. Our data exemplify a
real world’ cohort and highlight genuine complex day-to-day clin-
cal challenges in a LMIC setting. 
We used platelet count as a marker of liver disease, but this is
 non-specific approach. The sensitivity and specificity of APRI and
IB-4 varies between settings, with recent studies suggesting that
ut-off thresholds for patients with chronic HBV may need revis-
ng. 50 Further evaluation is specifically required in African popu-
ations, 21 particularly in the context of high HIV prevalence. 51 The
amma-glutamyl transpeptidase to platelet ratio (GPR) may be a
ore accurate biomarker of liver disease, 21 , 52 although poor corre-
ation with elastography scores is reported in HIV coinfected indi-
iduals. 51 In this study, we were unable to determine GPR as the
xtended panel of liver function tests required is not routinely col-
ected. 
Our observations are inevitably influenced by referral bias: pa-
ients with more advanced pathology are most likely to be diag-
osed and referred for tertiary-level assessment, and more likely to
emain under long term hospital follow-up. In the general popula-
ion, the majority of cases of HBV monoinfection are undiagnosed,
nd even those with a diagnosis are infrequently under routine
urveillance, less likely to be stratified for treatment, and rarely re-
eive a regular supply of appropriate therapy supported by clinical
onitoring. 18 
onclusions 
Our results demonstrate the potential impact of differences be-
ween referral, surveillance and therapy for HBV monoinfection in














































































































ontrast to HIV/HBV coinfection. By describing a neglected burden
f liver disease associated with CHB in this setting, we point to
 need for a reappraisal of guidelines, and enhanced investment
f resource, clinical care and infrastructure to provide a safer and
ore equitable service for patients with HBV monoinfection. High
tandards of provision of HIV services, with consistent access to
iagnosis, surveillance and TDF-based treatment, can be advanta-
eous in delivering a high standard of clinical care for those with
BV coinfection. In order to make progress towards 2030 elimina-
ion goals, service providers should capitalise on the existing in-
rastructure and investment deployed for HIV as both a precedent
nd a foundation for improved clinical care for HBV infection. 
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